
|Videos|May 11, 2022
Dr. Tanya Dorff discusses CAR T-cell research in prostate cancer
Author(s)Urology Times staff
Advertisement
Tanya Dorff, MD, discusses findings from a phase 1 clinical trial (NCT03873805) which explored the use of chimeric antigen receptor (CAR) T-cell therapy in patients with prostate cancer. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












